NSE SAILIFE · BSE 544306 · Biotechnology & Drugs · NIFTY 500
Sai Life Sciences Share Price
Sai Life Sciences Overview
Where the price stands, how it has moved and how it sits against its averages.
Sai Life Sciences shares last traded at ₹1,594.90 on the NSE, down 0.94% on the day. That is 6.0% below the 52-week high of ₹1,697.00 and 102.9% above the 52-week low of ₹786.15. The stock trades at 71.88× earnings, above the sector average of 46.34. Its market value is ₹33,957 Cr.
Price returns
Against the market: 1 Month ▲ +14.06% · 3 Months ▲ +37.44% · 6 Months ▲ +59.94% · This year ▲ +101.80% · 1 Year ▲ +97.93%
Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.
Moving averages — price is above 6 of 6
- Today's price₹1,594.90
- 10-day average₹1,593.39 ▲ price 0.1% above
- 5-day average₹1,578.76 ▲ price 1.0% above
- 20-day average₹1,556.36 ▲ price 2.5% above
- 50-day average₹1,436.42 ▲ price 11.0% above
- 100-day average₹1,303.84 ▲ price 22.3% above
- 300-day average₹1,117.90 ▲ price 42.7% above
Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.
Sai Life Sciences Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹2,192 Cr | ▲ +29.4% | ₹349 Cr | 15.9% | ₹16.43 | — |
| FY 2025 | ₹1,695 Cr | ▲ +15.7% | ₹170 Cr | 10.0% | ₹8.61 | — |
| FY 2024 | ₹1,465 Cr | ▲ +20.4% | ₹83 Cr | 5.7% | ₹3.98 | — |
| FY 2023 | ₹1,217 Cr | ▲ +40.0% | ₹10 Cr | 0.8% | ₹0.48 | — |
| FY 2022 | ₹870 Cr | — | ₹6 Cr | 0.7% | ₹0.30 | — |
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹554 Cr | ▼ −7.9% | ₹73 Cr | 13.2% | ₹3.46 |
| Q4 FY26 | ₹602 Cr | ▲ +8.2% | ₹104 Cr | 17.3% | ₹4.90 |
| Q3 FY26 | ₹556 Cr | ▲ +3.5% | ₹100 Cr | 18.0% | ₹4.71 |
| Q2 FY26 | ₹537 Cr | ▲ +8.3% | ₹84 Cr | 15.6% | ₹3.93 |
| Q1 FY26 | ₹496 Cr | ▼ −14.3% | ₹60 Cr | 12.2% | ₹2.83 |
| Q4 FY25 | ₹580 Cr | ▲ +31.8% | ₹88 Cr | 15.2% | ₹4.00 |
| Q3 FY25 | ₹440 Cr | ▲ +11.2% | ₹54 Cr | 12.2% | ₹2.84 |
| Q2 FY25 | ₹396 Cr | — | ₹42 Cr | 10.5% | ₹1.78 |
Balance sheet — FY26
- Total assets₹3,626 Cr
- Total liabilities₹1,142 Cr
- Shareholders' equity₹2,484 Cr
- Total debt₹288 Cr
- Cash & investments₹189 Cr
- Current ratio1.69×
- Operating margin (TTM)21.11%
- Net margin (TTM)16.07%
Cash flow — FY26
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY22–FY26
| ₹ crore | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Total revenue | 869.59 | 1,217.14 | 1,465.18 | 1,694.57 | 2,192.49 |
| Cost of revenue | 325.05 | 505.21 | 539.25 | 558.87 | 698.00 |
| Gross profit | 544.55 | 711.93 | 925.93 | 1,135.70 | 1,494.49 |
| Operating expenses | 838.48 | 1,151.07 | 1,299.13 | 1,425.67 | 1,735.23 |
| Operating income | 31.12 | 66.07 | 166.05 | 268.90 | 457.27 |
| Depreciation | 90.16 | 99.43 | 119.44 | 138.57 | 166.86 |
| Profit before tax | 9.70 | 16.41 | 109.23 | 227.70 | 466.19 |
| Tax | 3.47 | 6.42 | 26.43 | 57.57 | 117.28 |
| Net profit | 6.23 | 9.99 | 82.81 | 170.13 | 348.91 |
| EPS (₹) | 0.30 | 0.48 | 3.98 | 8.61 | 16.43 |
| Dividend per share (₹) | — | — | — | — | — |
| ₹ crore | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Total assets | 2,164.23 | 2,186.65 | 2,275.14 | 3,159.98 | 3,626.14 |
| Current assets | 945.38 | 963.95 | 945.11 | 1,504.51 | 1,410.53 |
| Cash & short-term investments | 215.94 | 204.91 | 184.66 | 372.25 | 188.91 |
| Inventory | 136.00 | 148.32 | 92.57 | 129.26 | 156.47 |
| Property, plant & equipment | 1,152.69 | 1,176.49 | 1,272.96 | 1,601.81 | 2,079.17 |
| Total liabilities | 1,285.67 | 1,298.55 | 1,299.99 | 1,031.62 | 1,142.45 |
| Current liabilities | 714.60 | 758.85 | 739.90 | 732.49 | 833.68 |
| Total debt | 965.93 | 932.85 | 928.14 | 352.38 | 288.45 |
| Total equity | 878.56 | 888.09 | 975.14 | 2,128.35 | 2,483.69 |
| ₹ crore | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| From operations | 104.87 | 219.40 | 263.09 | 314.04 | 509.13 |
| From investing | −103.71 | −101.78 | −192.38 | −536.67 | −395.41 |
| From financing | 71.92 | −200.65 | −95.30 | 301.43 | −123.68 |
| Capital expenditure | −206.91 | −113.08 | −181.69 | −369.28 | −592.96 |
| Dividends paid | — | — | — | — | — |
| Net change in cash | 75.15 | −80.25 | −23.56 | 79.08 | −9.14 |
What Analysts Say
Recommendations from 4 analysts who cover Sai Life Sciences.
▲ 4 bullish (100.0%) · 0 hold (0.0%) · ▼ 0 bearish (0.0%)
Votes
How the votes changed
| Rating | 3M ago | 2M ago | 1M ago | 1W ago | Now | 3-month change |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | ▲ +1 |
| Buy | 2 | 2 | 2 | 2 | 2 | — |
| Hold | 0 | 0 | 0 | 0 | 0 | — |
| Sell | 0 | 0 | 0 | 0 | 0 | — |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | — |
Analyst ratings are opinions, not a guarantee of returns.
Sai Life Sciences vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield | Rating |
|---|---|---|---|---|---|---|---|---|---|
| Sai Life Sciences | ₹1,594.90 | ▼ −0.94% | ₹33,957 Cr | 71.88 | 13.72 | — | 16.07% | 0.00% | This stock |
| Sun Pharmaceutical Industries | ₹1,853.00 | ▼ −0.64% | ₹4,44,586 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% | Moderately Bearish |
| Divi's Laboratories | ₹9,613.00 | ▲ +0.17% | ₹2,55,195 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% | Bullish |
| Torrent Pharmaceuticals | ₹4,935.00 | ▼ −0.90% | ₹1,87,705 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% | Bullish |
| Cipla | ₹1,404.00 | ▲ +1.74% | ₹1,13,423 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% | Neutral |
| Zydus Lifesciences | ₹1,180.00 | ▲ +0.90% | ₹1,17,705 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% | Bullish |
Rating = the data provider's overall technical view of each peer. Company names link to their own pages.
Sai Life Sciences Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Valuation Is the price reasonable?
Profitability Of every ₹100 of sales, how much is kept?
Returns & efficiency How well does it use its money?
Growth Is the business getting bigger?
Financial strength Can it pay its bills and debts?
Per share What each share stands for
The share price is 13.60× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 82 metrics from the data provider
Valuation
Per share
Margins
Growth
Financial strength
Returns & efficiency
Price & volume
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
- Dividend yield0.00%
- Payout ratio0.00%
No dividends on record.
Corporate calendar
- MeetingAnnual General Meeting
- BoardQuarterly Results
- BoardAudited Results
- BoardQuarterly Results
- BoardQuarterly Results
- MeetingAnnual General Meeting
- BoardQuarterly Results
- MeetingPostal Ballot
Show 2 older events
- BoardAudited Results
- BoardQuarterly Results
About Sai Life Sciences
Biotechnology & Drugs
Sai Life Sciences Limited is an India-based company. The Company is a contract research, development, and manufacturing organization (CRDMO). It offers a range of tailor-made services for biotech firms or global pharma company requirements. Its services include integrated drug discovery services, drug metabolism and pharmacokinetics (DMPK), synthetic & medicinal chemistry, biology services, general toxicology, genotoxicity, and computational chemistry services. It also offers chemistry, manufacturing and controls (CMC) services which include route scouting, process familiarization, optimization & development, analytical method development & validation, process safety evaluation, stability studies, and early phase scale-up. Its discovery biology facility provides exploratory biology services to the expanding array of start-up and biotech companies in the Boston area and to companies in North America.
Key people
- Kanumuri Ranga RajuExecutive Chairman of the Board
- Krishnam Raju KanumuriChief Executive Officer, Managing Director
- Sivaramakrishnan ChittorAdditional Whole-Time Director and Chief Financial Officer
- Runa KaranChief Compliance Officer, Company Secretary
Company facts
- NSE symbolSAILIFE
- BSE code544306
- ISININE570L01029
- IndustryBiotechnology & Drugs
- IndexNIFTY 500
- Market cap₹33,957 Cr
- Revenue (FY26)₹2,192 Cr
- Net profit (FY26)₹349 Cr
In the News
Recent headlines about Sai Life Sciences — they open on Mint in a new tab.
- Stock market today: Trade guide for Sensex, Nifty 50, crude oil to gold | Eight stocks to buy
The Indian stock market is set to open lower on September 10, as global cues remain mixed. The Sensex and Nifty 50 ended the previous session down, with market analysts predicting further weakness unless certain support levels are reclaimed.
10 Sep 2026 · 4 min read · Mint ↗ - Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —2 September 2026
Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today —GHCL Textiles, Gmm Pfaudler, Tarsons Products, Aeroflex Industries, and Sai Life Sciences.
2 Sep 2026 · 6 min read · Mint ↗ - Welspun Corp, Piramal Finance, Divis Labs among 12 BSE 500 stocks that jumped to their record highs today; do you own?
Some 17 stocks scaled their 52-week highs in the BSE 500 index, among which 12, including Welspun Corp, Piramal Finance, and Divis Laboratories, jumped to their record highs.
28 Aug 2026 · 2 min read · Mint ↗ - Stock market today: Gift Nifty hints a flat-to-negative start; eight day trading stocks to buy on Friday, 28 August
The Indian stock market is set to open flat to negative on 28 August, following global cues. Both the Sensex and the Nifty 50 ended lower earlier. Crude oil prices dipped, with escalating US-Iran tensions affecting market sentiment amid mixed global cues and an uncertain financial outlook.
28 Aug 2026 · 5 min read · Mint ↗ - Buy or sell: Gift Nifty signals gap-up start | Vaishali Parekh recommends three stocks to buy today — 26 August 2026
Buy or sell indicator: Vaishali Parekh recommends three stocks to buy today — Astral, Sai Life Sciences, and ICICI Bank
26 Aug 2026 · 2 min read · Mint ↗ - Stock market today: Gift Nifty hints a gap-down start; eight day trading stocks to buy on Friday, 7 August
Indian stock market indices Sensex and Nifty 50 are expected to open lower on 7 August due to rising crude oil prices and Middle East tensions. Brent crude has surged, raising concerns over energy supplies and inflation. The Gift Nifty suggests a cautious start for domestic equities.
7 Aug 2026 · 4 min read · Mint ↗ - Stock market today: Gift Nifty hints a positive start; eight day trading stocks to buy on Wednesday, 29 July
The Indian stock market is expected to open higher on July 29, alongside stable global cues, despite a subdued previous session. Oil prices rebounded after a pause in US-Iran hostilities, with Brent crude rising over 3%. Investor focus is on the Fed's monetary policy decision.
29 Jul 2026 · 4 min read · Mint ↗ - Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
20 Jul 2026 · 2 min read · Mint ↗
Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →